E

EuBiologics Co Ltd
KOSDAQ:206650

Watchlist Manager
EuBiologics Co Ltd
KOSDAQ:206650
Watchlist
Price: 12 740 KRW -2% Market Closed
Market Cap: 465.4B KRW
Have any thoughts about
EuBiologics Co Ltd?
Write Note
EuBiologics Co Ltd
/
Income Statement
/
Revenue

EuBiologics Co Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

EuBiologics Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
E
EuBiologics Co Ltd
KOSDAQ:206650
Revenue
₩86.1B
CAGR 3-Years
29%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Revenue
₩2.7T
CAGR 3-Years
11%
CAGR 5-Years
23%
CAGR 10-Years
23%
SK Bioscience Co Ltd
KRX:302440
Revenue
₩369.5B
CAGR 3-Years
18%
CAGR 5-Years
30%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Revenue
₩363.8B
CAGR 3-Years
14%
CAGR 5-Years
12%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Revenue
₩296.6B
CAGR 3-Years
30%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Revenue
₩90.8B
CAGR 3-Years
34%
CAGR 5-Years
42%
CAGR 10-Years
N/A
No Stocks Found

EuBiologics Co Ltd
Glance View

Market Cap
464.4B KRW
Industry
Biotechnology

EuBiologics Co., Ltd. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 323 full-time employees. The company went IPO on 2017-01-24. The firm operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.

Intrinsic Value
17 421.92 KRW
Undervaluation 27%
Intrinsic Value
Price
E
What is Intrinsic Value?

See Also

What is EuBiologics Co Ltd's Revenue?
Revenue
86.1B KRW

Based on the financial report for Sep 30, 2024, EuBiologics Co Ltd's Revenue amounts to 86.1B KRW.

What is EuBiologics Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
22%

Over the last year, the Revenue growth was 44%. The average annual Revenue growth rates for EuBiologics Co Ltd have been 29% over the past three years , 22% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.